此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Early Sepsis Detection Using NEWS2 and Circulating H3.1 Nucleosomes in Emergency Departments (DETECSEPS)

2026年11月11日 更新者:Assistance Publique - Hôpitaux de Paris

Real-life Evaluation of the Impact of Early Detection of Sepsis With the NEWS2 Clinical Alert Score Combined to Circulating Concentrations of the H3.1 Nucleosome, on the Care Pathway of Adults Presenting to the Emergency Department With a Proven or Strongly Suspected Infection

DETECSEPS is a multicentre, randomized, open-label trial sponsored by Assistance Publique - Hôpitaux de Paris, under the scientific leadership of IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, led by Professor Djillali Annane.

The study evaluates whether an early sepsis detection strategy combining the National Early Warning Score 2 (NEWS2) and circulating H3.1 nucleosome concentrations improves care pathways compared with usual care in adults presenting to emergency departments with suspected or confirmed infection and at least one risk factor for sepsis.

The strategy aims to support timely recognition and management of sepsis and to identify patients suitable for discharge with ambulatory follow-up when hospital admission is not otherwise indicated. The study will assess care pathway optimization at 24 hours, clinical outcomes, health-related quality of life, return to usual activities, and economic and environmental outcomes.

研究概览

详细说明

DETECSEPS will enrol 1,000 adults across participating emergency departments. Participants will be randomized to either a diagnostic and management strategy guided by NEWS2 and circulating H3.1 nucleosome concentrations or usual care.

In the intervention group, the combined algorithm will guide clinical management and disposition according to the approved study protocol. The description of the algorithm will specify the actions associated with each combination of NEWS2 and H3.1 categories, including discharge with ambulatory follow-up, hospital admission, early sepsis management, and assessment for intensive care admission.

In the usual-care group, management will follow routine clinical practice. Research H3.1 results will not be disclosed to treating clinicians. The record will distinguish any NEWS2 score calculated specifically for research from physiological measurements and assessment tools available during routine care.

The primary outcome is the proportion of participants with an optimized care pathway at 24 hours. Participants will be followed for six months.

IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center is responsible for the scientific leadership of the study. Assistance Publique - Hôpitaux de Paris is the study sponsor.

研究类型

介入性

注册 (估计的)

1000

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Boulogne-Billancourt、法国
        • Hôpital Ambroise Paré - AP-HP
        • 接触:
      • Lyon、法国
        • Hôpital de la Croix Rousse - HCL
        • 接触:
      • Lyon、法国
      • Lyon、法国
      • Paris、法国
        • Hôpital Bichat - AP-HP
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria

  1. All genders patients

  2. Aged of 18 years or older

  3. Proven or suspected infection

  4. At least one risk factor for sepsis (cf HAS recommendations) :

    • Age/frailty : >65 year; Clinical Frailty Scale ≥5; postpartum; Cognitive or motor disabilities; Implantable medical device; Recent surgery

    • Inborn immune deficit

    • Acquired immune deficit :

      • Diseases related : Cancer, Transplant patient, Chronic inflammatory or autoimmune disease, HIV, Asplenic anatomical or functional (Sickle cell disease)
      • Treatment related : Long-term corticotherapy, chemotherapy, Biotherapy, Cell therapy, radiotherapy, Immunosuppressive drugs,
    • Non immune disorders : Cirrhosis, chronic liver disease, chronic renal insufficiency, chronic cardiac failure, diabetes with complication or uncontrolled, malnutrition, previous episode of sepsis

  5. Informed consent

Exclusion Criteria:

  1. Refused to consent participating in the study,
  2. Any condition for which patient's primary physician will consider inappropriate enrolling patient in the study,
  3. Previous enrolment
  4. Pregnancy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:NEWS2 and H3.1-guided diagnostic and management strategy

Clinical management and disposition will be guided by a prespecified algorithm combining NEWS2 and circulating H3.1 nucleosome concentrations. Decisions will follow the thresholds and management rules specified in the protocol.

Upon randomization, NEWS2 score and plasma level of H3.1 will be provided to the investigator and healthcare staff to guide management as per decision tree below :

  • If NEWS2 ≤2 AND H3.1 ≤50 ng/ml, the progression to sepsis is very unlikely or unlikely and the patient can be discharged home with ambulatory follow-up via teleconsultation.
  • If NEWS2 ≥5 and H3.1 ≥740 ng/ml, the progression to sepsis is likely or very likely and the 3-hour bundle of the Surviving Sepsis Campaign will be implemented and admission to the ICU within 6 hours of arrival at Emergency Department is required.
  • In any other case, patients will be monitored in the emergency department and NEWS 2 and plasma H3.1 level are recorded again at 3 hours.

This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system.

The result will not be disclosed to the investigators and healthcare staff in the control arm

The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system:

  1. respiration rate
  2. oxygen saturation
  3. systolic blood pressure
  4. pulse rate
  5. level of consciousness or new confusion
  6. temperature

The result will not be disclosed to the investigators and healthcare staff in the control arm

其他:Usual care

Comparator arm description: Participants will receive usual diagnostic assessment and clinical management. H3.1 nucleosome concentrations will be measured for research purposes, but results will not be disclosed to treating clinicians.

This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system.

The result will not be disclosed to the investigators and healthcare staff in the control arm

The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system:

  1. respiration rate
  2. oxygen saturation
  3. systolic blood pressure
  4. pulse rate
  5. level of consciousness or new confusion
  6. temperature

The result will not be disclosed to the investigators and healthcare staff in the control arm

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of patients with optimized care pathway
大体时间:24 hours after inclusion

The best care pathway is defined by: discharge to home in the absence of confirmed sepsis, or hospitalization whenever any other reason than sepsis will mandate hospital admission

If sepsis is confirmed:

  • Implementation of good clinical practice recommendations within 3 hours of arrival at ED (3-hour bundle of the Surviving Sepsis Campaign & HAS recommendations)
  • ICU admission within 6 hours of arrival at ED
24 hours after inclusion

次要结果测量

结果测量
措施说明
大体时间
Death rate
大体时间:At 6 months
At 6 months
Cumulative incidence of direct ICU admission
大体时间:Up to 6 months
Up to 6 months
Cumulative incidence of secondary ICU admission
大体时间:Up to 6 months

ie after admission to ward

Up to 6 months
Proportion of patients with cognitive, psychological, or physical sequelae
大体时间:Up to 6 months
Up to 6 months
Proportion of patients requiring renal, respiratory, or cardiovascular support
大体时间:Up to day 7

Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery

Up to day 7
Proportion of patients requiring renal, respiratory, or cardiovascular support
大体时间:Up to day 28

Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery

Up to day 28
Time to discharge to home
大体时间:Up to 6 months
Up to 6 months
Time to resume previous social and professional activities
大体时间:Up to 6 months
Up to 6 months
Quality of life - EQ-5D-5L
大体时间:At 6 months

The EQ-5D-5L is a patient-reported questionnaire assessing health-related quality of life across five dimensions, with higher index and EQ VAS scores indicating better health status

At 6 months
Quality of life - SF36
大体时间:At 6 months

The SF-36 is a 36-item patient-reported questionnaire assessing health-related quality of life across eight physical and mental health domains, with higher scores indicating better health status and functioning.

At 6 months
Cost of strategies and care pathways
大体时间:At 6 months

Costs of strategies and care pathways at 6 months with and without early H3.1 concentrations and the NEWS2 clinical score, incremental cost-effectiveness ratio calculated by the ratio of the difference in costs to the difference in survival without sequelae and without organ failure at 6 months.

At 6 months
Proportion of cases for which the combined diagnostic protocol is applied as intended
大体时间:Up to 6 months

e.g., correct use of NEWS2 and H3.1 nucleosome testing

Up to 6 months
Proportion of test results available below a meaningful clinical duration to allow for patient management.
大体时间:Up to 6 months
Up to 6 months
Proportion of appropriate integration of tests results within clinical workflow
大体时间:Up to 6 months
Up to 6 months
Proportion of avoided hospitalization among patients receiving the intervention
大体时间:Up to 6 months
Up to 6 months
Evolution of the proportion of eligible patients included over time
大体时间:Up to 6 months
Up to 6 months
Environmental impact of study-related procedures
大体时间:Up to 6 months

The environmental footprint of each component of the research process will be assess, including:

  • Biological sampling: Biomarkers will be measured from routine care tubes, avoiding the use of dedicated research tubes, which often expire unused and contribute to waste.
  • Patient transport: No additional on-site visits will be required for the study, limiting travel-related emissions (Lyle et al., BMJ, 2009).
  • Study documentation: Digital consent forms (e-consent) will be preferred. When choosing between paper or electronic formats, the environmental impact of printing, document replacement after amendments, and digital storage will be considered.

All study procedures will be reviewed according to the guidance proposed by Griffiths et al. (BMJ Open, 2024), which identified high-impact areas in clinical trials. The goal is to apply these recommendations throughout the study.

Up to 6 months
Life cycle analyse (LCA)
大体时间:Up to 6 months

Life cycle analyses (LCA) of the new algorithm and its associated device. It will be based on the Life Cycle Assessment (LCA) framework proposed by Ashby (Materials and the Environment, 2013), using Granta EduPack® software tools.

Up to 6 months
LCA comparison of the two clinical strategies
大体时间:Up to 6 months

The two clinical strategies will be compared using LCA to assess their respective environmental impacts from patient inclusion to the end of follow-up. This approach is inspired by previous work (Makhloufi et al., Nephrol Dial Transplant, 2024), integrating medical and ecological outcomes.

The average carbon emissions and water consumption between the two groups will be compared by collecting all activities from the time of inclusion until the end of follow-up in the study.

Up to 6 months

其他结果措施

结果测量
措施说明
大体时间
Circulating levels of C-reactive protein, procalcitonin, NETs, neutrophil degranulation markers, cytokines and chemokines
大体时间:At baseline, day 1 and day 7
At baseline, day 1 and day 7
Multi-omic profile
大体时间:At baseline

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At baseline
Multi-omic profile
大体时间:At day 1

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At day 1
Multi-omic profile
大体时间:At day 7

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At day 7
Innate immune cells activation markers and sub-populations
大体时间:At baseline

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At baseline
Innate immune cells activation markers and sub-populations
大体时间:At day 1

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At day 1
Innate immune cells activation markers and sub-populations
大体时间:At day 7

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At day 7

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Djillali Annane, MD PhD、IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, AP-HP, Université Paris-Saclay

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年12月2日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2026年10月30日

首先提交符合 QC 标准的

2026年11月11日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

According to DETECSEPS consortium data management plan, upon request to IHU SEPSIS and to APHP

IPD 共享时间框架

Within 6 months from publication of the study results

IPD 共享访问标准

Upon request to IHU SEPSIS and to APHP according to the data management plan of the Consortium

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅